The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Reports |

Malignant Insulinoma: Effects of a Somatostatin Analog (Compound 201-995) on Serum Glucose, Growth, and Gastro-Entero-Pancreatic Hormones

[+] Article, Author, and Disclosure Information

Grant support: in part by Sandoz Pharmaceuticals, East Hanover, New Jersey; the Veterans Administration; the National Institutes of Health, Clinical Research Center (GCRC, RR-34); and The CRC Core Laboratory of The Ohio State University Hospitals.

▸Requests for reprints should be addressed to Thomas M. O'Dorisio, M.D.; N1123 Doan Hall, Ohio State University Hospitals, 410 W. 10th Avenue; Columbus, OH 43210.

The Ohio State University College of Medicine; Columbus, Ohio.

Ann Intern Med. 1985;103(2):223-225. doi:10.7326/0003-4819-103-2-223
Text Size: A A A
This excerpt has been provided in the absence of an abstract.

Various therapies have been used to treat patients with active malignant insulinoma (1-3), which comprises 10% of all beta-cell tumors of the pancreas (1). Somatostatin, a tetradecapeptide found in the hypothalamus and gastro-entero-pancreatic system, suppresses several endocrine hormones (4). However, because of the short halflife (5 to 10 minutes) of endogenous somatostatin, several analogs with longer-acting properties have been synthesized (5). Recently, compound 201-995 (Sandoz Pharmaceutical, Inc., East Hanover, New Jersey), an octapeptide with a 10 to 20 times longer half-life and a 50 to 100 times greater potency has become available in United States. We report the use of


First Page Preview

View Large
First page PDF preview





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.